Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Left ventricular myocardial crypts: morphological patterns and prognostic implications

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Left ventricular trabeculation and major adverse cardiovascular events: the Copenhagen General Population Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Atrial fibrillation (AF) in heart failure (HF) patients has been associated with a worse outcome. Similarly, excessive supraventricular ectopic activity (ESVEA) has been linked to development of AF, stroke and death. This study aimed to investigate AF and ESVEA's association with outcomes and effect of prophylactic implantable cardioverter defibrillator (ICD) implantation in non-ischemic HF patients.

METHODS: A total of 850 patients with non-ischemic HF, left ventricle ejection fraction ≤35%, and elevated N-terminal pro-brain natriuretic peptides underwent 24-hours Holter recording. The presence of AF (≥30 seconds) and ESVEA (≥30 supraventricular ectopic complexes (SVEC) per hour or run of SVEC ≥20 beats) were registered. Outcomes were all-cause mortality, cardiovascular death (CVD) and sudden cardiac death (SCD).

RESULTS: AF was identified in 188 patients (22%), and ESVEA in 84 patients (10%). After 4 years and 11 months of follow-up, a total of 193 patients (23%) had died. AF was associated with all-cause mortality (HR 1.44; CI 1.04-1.99; P=0.03) and CVD (HR 1.59; CI 1.07-2.36; P=0.02). ESVEA was associated with all-cause mortality (HR 1.73; CI 1.16-2.57; P=0.0073) and CVD (HR 1.76; CI 1.06-2.92; P=0.03). Neither AF nor ESVEA was associated with SCD. ICD implantation was not associated with an improved prognosis for neither AF (P-value for interaction=0.17), nor ESVEA (P-value for interaction=0.68).

CONCLUSION: Both AF and ESVEA were associated with worsened prognosis in non-ischemic HF. However, ICD implantation was not associated with an improved prognosis for either group.

Original languageEnglish
JournalAmerican Heart Journal
Volume232
Pages (from-to)61-70
Number of pages10
ISSN0002-8703
DOIs
Publication statusPublished - 2020

Bibliographical note

Copyright © 2020 Elsevier Inc. All rights reserved.

ID: 61235275